GlassScriptPhysician profile
Nency Sangani
NPI 1952089062
$6,610.13
in general payments reported to CMS, 2019-2025
46 companies · $3,931 in 2025
The $3,931 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $365 · 2024: $2,314 · 2025: $3,931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,610.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,122.35 | 2024-2025 | Mavenclad |
| Abbvie INC. | $932.14 | 2023-2025 | |
| Lundbeck LLC | $629.83 | 2023-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $379.76 | 2024-2025 | Xcopri |
| Biogen, INC. | $363.01 | 2024-2025 | Tysabri, Vumerity, Plegridy |
| Eisai INC. | $330.76 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $238.73 | 2024-2025 | Ultomiris |
| Tg Therapeutics, INC. | $228.09 | 2024-2025 | |
| Genentech USA, INC. | $172.10 | 2024-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Lilly USA, LLC | $154.85 | 2023-2025 | Kisunla, Emgality, Amyvid |
| Novartis Pharmaceuticals Corporation | $134.79 | 2024-2025 | |
| Genzyme Corporation | $128.72 | 2024-2025 | |
| Csl Behring | $123.72 | 2024-2025 | Hizentra |
| Pfizer INC. | $115.30 | 2024-2025 | |
| Catalyst Pharmaceuticals, INC. | $110.81 | 2024-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $94.49 | 2024 | Rexulti, Nuedexta |
| Mallinckrodt Hospital Products INC. | $86.02 | 2025 | Acthar |
| Ucb, INC. | $79.44 | 2023-2025 | Zilbrysq, Briviact |
| Alnylam Pharmaceuticals INC. | $76.92 | 2023-2025 | Onpattro, Givlaari |
| Celgene Corporation | $73.88 | 2024-2025 | Zeposia |
| Cycle Pharmaceuticals INC | $71.56 | 2024-2025 | Tascenso Odt, Bafiertam, Ormalvi |
| Kyowa Kirin, INC. | $71.08 | 2024 | Nourianz |
| Astrazeneca Pharmaceuticals LP | $65.33 | 2024-2025 | Wainua |
| Vanda Pharmaceuticals INC. | $63.60 | 2024-2025 | Ponvory |
| Kedrion Biopharma, INC. | $62.86 | 2024-2025 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Averitas Pharma INC. | $56.72 | 2023-2025 | Qutenza |
| Xeris Pharmaceuticals, INC. | $56.20 | 2024-2025 | Keveyis |
| Amgen INC. | $55.18 | 2025 | Uplizna |
| Argenx US, INC. | $53.74 | 2025 | Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $47.11 | 2024-2025 | Austedo Xr, Austedo Xr |
| Acadia Pharmaceuticals INC | $44.11 | 2024-2025 | Nuplazid, Daybue |
| Grifols USA, LLC | $39.46 | 2025 | Gamunex-C |
| Ipsen Biopharmaceuticals, INC | $37.22 | 2025 | Dysport |
| Ani Pharmaceuticals, INC. | $36.69 | 2025 | Purified Cortrophin Gel |
| Genentech, INC. | $31.57 | 2025 | Ocrevus |
| Neurelis, INC. | $28.49 | 2024-2025 | Valtoco |
| Cala Health, INC. | $25.38 | 2025 | Cala Kiq |
| Livanova USA, INC. | $24.77 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Invivyd INC | $24.19 | 2025 | Pemgarda |
| Insightec,INC | $23.78 | 2024 | Exablate |
| Amylyx Pharmaceuticals, INC. | $23.59 | 2024 | Relyvrio |
| Acorda Therapeutics, INC | $21.04 | 2024 | Inbrija, Ampyra |
| Tanabe Pharma America, INC. | $19.27 | 2025 | Radicava |
| Octapharma USA, INC. | $18.86 | 2025 | Panzyga |
| Axsome Therapeutics, INC. | $18.22 | 2023 | Sunosi |
| Mylan Specialty L.P. | $14.40 | 2024 | Glatiramer Acetate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nency Sangani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.